Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug187 | Acalabrutinib Wiki | 0.35 |
| drug2575 | No intervention Wiki | 0.15 |
| drug2916 | Placebo Wiki | 0.03 |
Navigate: Correlations HPO
There are 2 clinical trials
This study will the safety of a 96-hour intravenous vitamin C infusion protocol (50 mg/kg every 6 hours) in patients with hypoxemia and suspected COVID-19.
Description: COVID disease status will be measured by the 9-point (from 0 to 8) World Health Organization (WHO) ordinal scale for disease improvement at 28 days.
Measure: Change in COVID disease status Time: Baseline to 28, 60 and 90 daysDescription: Change in serum oxalate levels
Measure: Renal safety biomarkers - serum oxalate Time: On days 5,7 and 14Description: Microscopic analysis of urine for presence of oxalate stones
Measure: Renal safety biomarkers - urine oxalate stones Time: On days 5,7 and 14Description: 24-hour urine oxalate levels
Measure: Renal safety biomarkers - 24-hour urine oxalate levels Time: On days 5,7 and 14Description: Renal-failure free days, with AKI defined by the KDIGO criteria
Measure: Acute Kidney Injury-free days Time: On day 28, 90Description: Mortality by all causes
Measure: Number of deaths Time: On day 28, 60 and 90 daysDescription: Difference in plasma ferritin levels in ng/mL, compared to baseline levels
Measure: Change in plasma ferritin levels Time: Days 1-7 compared with baselineDescription: Difference in D-dimer levels in mcg/mL, compared to baseline levels
Measure: Change in plasma D-dimer levels Time: Days 1-7 compared with baselineDescription: Difference in lactate dehydrogenase (LDH) levels in units/L, compared to baseline levels
Measure: Change in serum lactate dehydrogenase (LDH) levels Time: Days 1-7 compared with baselineDescription: Difference in syndecan-1 levels in ng/mL, to with baseline levels
Measure: Change in plasma syndecan-1 levels Time: Days 1-7 compared with baselineDescription: Difference in cell-free DNA levels in ng/μL, compared to baseline levels
Measure: Change in plasma cell-free DNA levels Time: Days 1-7 compared with baselineDescription: Difference in plasma IL-6 levels in pg/mL, compared to baseline levels
Measure: Change in plasma IL-6 levels Time: Days 1-7 compared with baselineDescription: Respiratory failure defined as resource utilization requiring at least 1 of the following: Endotracheal intubation and mechanical ventilation, Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates >20L/min with fraction of delivered oxygen ≥0.5), noninvasive positive pressure ventilation, extracorporeal membrane oxygenation
Measure: Proportion of patients alive and free of respiratory failure Time: At 28-daysDescription: Percentage of patients alive and not requiring invasive mechanical ventilation
Measure: Proportion of patients alive and free of invasive mechanical ventilation Time: At 28-daysPrevious research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS). However, it is not known if early administration of HDIVC could prevent progression to ARDS. We hypothesize that HDIVC is safe and tolerable in Coronavirus disease 2019 (COVID-19) subjects given early or late in the disease course and may reduce the risk of respiratory failure requiring mechanical ventilation and development of ARDS along with reductions in supplemental oxygen demand and inflammatory markers.
Description: Occurrence of adverse events during study drug infusion
Measure: Incidence of adverse events Time: Days 1-4Description: Occurrence of serious adverse events during study drug infusion
Measure: Incidence of serious adverse reactions Time: Days 1-4Description: Occurrence of adverse reactions during study drug infusion
Measure: Incidence of adverse reactions Time: Days 1-4Description: Documented days free off mechanical ventilation the first 28 days post enrollment
Measure: Ventilator-free days Time: Days 1-28Description: Documented days free of ICU admission the first 28 days post enrollment
Measure: ICU-free days Time: Days 1-28Description: Documented days free of hospital admission the first 28 days post enrollment
Measure: Hospital-free days Time: Days 1-28Description: Incidence of mortality at 28 days by all causes
Measure: All-cause mortality Time: Days 1-28Description: SpO2 (% peripheral oxygenation saturation) will be divided by fraction of inspired oxygen (FiO2) at start of study infusion and compared with S/F ratio at end of study infusion
Measure: Change in S/F ratio during HDIVC infusion Time: Days 1-4Description: The difference in serum CRP during HDIVC infusion reported in mg/dL
Measure: C-reactive protein (CRP) Time: Days 1-4Description: The difference in LDH during HDIVC infusion will be reported in IU/L
Measure: Lactate dehydrogenase (LDH) Time: Days 1-4Description: The difference in D-dimer during HDIVC infusion will be reported in ug/mL
Measure: D-dimer Time: Days 1-4Description: The difference in lymphocyte count during HDIVC infusion will be reported in 10e3/uL
Measure: Lymphocyte count Time: Days 1-4Description: The NLR will be calculated by dividing the absolute neutrophil count (10e3/uL) over the absolute lymphocyte count (10e3/uL) and ratio compared with Day 1 versus Day 4
Measure: Neutrophil to Lymphocyte ratio (NLR) Time: Days 1-4Description: The difference in serum ferritin will be calculated from the start of HDIVC infusion to day 4 and reported as ng/mL
Measure: Serum Ferritin Time: Days 1-4Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports